-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca Wins Approvals for Generalized Myasthenia Gravis Drug Klygefa in US, EU

MT Newswires·11/16/2026 05:31:58
Listen to the news
05:31 AM EST, 11/16/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) secured regulatory approvals in the US and the European Union for its generalized myasthenia gravis therapy Klygefa, or gefurulimab. Klygefa is aimed at treating the rare autoimmune disorder in adults who are anti-acetylcholine receptor antibody-positive, the drugmaker said Monday in two separate releases. The drug is self-administered subcutaneously once weekly via an autoinjector to treat the disorder, which creates reduced muscle function and severe muscle weakness. The decisions make Klygefa the first and only approved dual-binding nanobody C5 inhibitor in the US and EU, the company said. The approvals by the US Food and Drug Administration and the EU are backed by the positive results of the Prevail phase 3 study, in which the drug its primary endpoint. In the study, Klygefa showed improvement from baseline in the myasthenia gravis activities of daily living total score at week 26, compared with placebo. A clinically meaningful improvement was observed as early as week one and was sustained through week 26. The safety profile of Klygefa was also in line with previous trials of C5 inhibitors eculizumab and ravulizumab in generalized myasthenia gravis. The drug is also already approved in Japan and other countries for certain adults with generalized myasthenia gravis, while regulatory submissions in China and some other jurisdictions are under review. AstraZeneca's shares edged higher in London and Stockholm during early trading.